Victor M Lu1, Anshit Goyal2, Adrian Lee3, Mark Jentoft4, Alfredo Quinones-Hinojosa5, Kaisorn L Chaichana6. 1. Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, 2050, Australia. z5134616@unsw.edu.au. 2. Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic, Rochester, MN, USA. 3. Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia. 4. Department of Pathology, Mayo Clinic, Jacksonville, FL, USA. 5. Department of Neurosurgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. 6. Department of Neurosurgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Chaichana.Kaisorn@mayo.edu.
Abstract
BACKGROUND: Mutations in the telomerase reverse transcriptase promoter (TERTp) region have been associated with worse prognosis in some cancers. Meningiomas are the most common type of primary central nervous tumors, and evaluation of the prognostic significance of TERTp mutations across the literature is lacking. The aim of this study was to pool all current evidence to assess for clinical relevance of TERTp mutations in meningioma and survival effect. METHODS: Searches of seven electronic databases from inception to September 2018 were conducted following the appropriate guidelines. Two hundred and twenty seven articles were identified for screening. Hazard ratio (HR) and mean difference (MD) statistics were obtained and pooled utilizing both fixed- and random-effect (RE) models. Meta-regression was utilized to determine potential sources of heterogeneity and statistical influence. RESULTS: A total of five retrospective observational cohort studies describing 532 meningioma patients satisfied selection criteria. The incidence of TERTp mutations was 8%, and was associated with significantly worse prognosis (HR 3.79; P = 0.005) and significantly shorter overall survival (MD 59.8 months; P = 0.037) by RE modelling. Meningioma grade was not significantly associated with a TERTp mutation effect, however, preliminary meta-regression trends indicated this may be significant once greater statistical power is achieved. CONCLUSION: The current evidence indicates the presence of a TERTp mutation in meningioma can be associated with worse prognosis, and shorter overall survival. Routine detection in greater numbers will allow for further validation, as well as delineate the effect across histological grades. By identifying this subgroup of meningioma patients early in management, it may support more frequent follow-up and aggressive management to optimize survival outcomes.
BACKGROUND: Mutations in the telomerase reverse transcriptase promoter (TERTp) region have been associated with worse prognosis in some cancers. Meningiomas are the most common type of primary central nervous tumors, and evaluation of the prognostic significance of TERTp mutations across the literature is lacking. The aim of this study was to pool all current evidence to assess for clinical relevance of TERTp mutations in meningioma and survival effect. METHODS: Searches of seven electronic databases from inception to September 2018 were conducted following the appropriate guidelines. Two hundred and twenty seven articles were identified for screening. Hazard ratio (HR) and mean difference (MD) statistics were obtained and pooled utilizing both fixed- and random-effect (RE) models. Meta-regression was utilized to determine potential sources of heterogeneity and statistical influence. RESULTS: A total of five retrospective observational cohort studies describing 532 meningiomapatients satisfied selection criteria. The incidence of TERTp mutations was 8%, and was associated with significantly worse prognosis (HR 3.79; P = 0.005) and significantly shorter overall survival (MD 59.8 months; P = 0.037) by RE modelling. Meningioma grade was not significantly associated with a TERTp mutation effect, however, preliminary meta-regression trends indicated this may be significant once greater statistical power is achieved. CONCLUSION: The current evidence indicates the presence of a TERTp mutation in meningioma can be associated with worse prognosis, and shorter overall survival. Routine detection in greater numbers will allow for further validation, as well as delineate the effect across histological grades. By identifying this subgroup of meningiomapatients early in management, it may support more frequent follow-up and aggressive management to optimize survival outcomes.
Authors: Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers Journal: Neuro Oncol Date: 2012-03-09 Impact factor: 12.300
Authors: David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza Journal: BMJ Date: 2004-06-19
Authors: Ali Fuat Okuducu; Ulrich Zils; Silke A M Michaelis; Christian Mawrin; Andreas von Deimling Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Kaisorn L Chaichana; Courtney Pendleton; Hasan Zaidi; Alessandro Olivi; Jon D Weingart; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quiñones-Hinojosa Journal: World Neurosurg Date: 2012-03-30 Impact factor: 2.104
Authors: Alfredo Quiñones-Hinojosa; Tania Kaprealian; Kaisorn L Chaichana; Nader Sanai; Andrew T Parsa; Mitchel S Berger; Michael W McDermott Journal: Can J Neurol Sci Date: 2009-09 Impact factor: 2.104
Authors: David Pasquier; Stefan Bijmolt; Theo Veninga; Nicolas Rezvoy; Salvador Villa; Marco Krengli; Damien C Weber; Brigitta G Baumert; Emine Canyilmaz; Deniz Yalman; Ewa Szutowicz; Tzahala Tzuk-Shina; René O Mirimanoff Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: Akash J Patel; Ying-Wooi Wan; Rami Al-Ouran; Jean-Pierre Revelli; Maria F Cardenas; Mazen Oneissi; Liu Xi; Ali Jalali; John F Magnotti; Donna M Muzny; HarshaVardhan Doddapaneni; Sherly Sebastian; Kent A Heck; J Clay Goodman; Shankar P Gopinath; Zhandong Liu; Ganesh Rao; Sharon E Plon; Daniel Yoshor; David A Wheeler; Huda Y Zoghbi; Tiemo J Klisch Journal: Proc Natl Acad Sci U S A Date: 2019-10-07 Impact factor: 11.205
Authors: Arbaz A Momin; Jianning Shao; Pranay Soni; João Paulo Almeida; John H Suh; Erin S Murphy; Samuel T Chao; Lilyana Angelov; Alireza M Mohammadi; Gene H Barnett; Pablo F Recinos; Varun R Kshettry Journal: J Neurooncol Date: 2021-02-15 Impact factor: 4.130
Authors: So Yeon Won; Jun Ho Lee; Narae Lee; Yae Won Park; Sung Soo Ahn; Jinna Kim; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Michelle A Wedemeyer; Ivo Muskens; Ben A Strickland; Oscar Aurelio; Vahan Martirosian; Joseph L Wiemels; Daniel J Weisenberger; Kai Wang; Debraj Mukerjee; Suhn K Rhie; Gabriel Zada Journal: Neurooncol Adv Date: 2022-06-06
Authors: Alexander F Haddad; Jacob S Young; Ishan Kanungo; Sweta Sudhir; Jia-Shu Chen; David R Raleigh; Stephen T Magill; Michael W McDermott; Manish K Aghi Journal: Front Oncol Date: 2020-08-28 Impact factor: 6.244